In Colorectal Cancer, Chemo-Induced Volume Elevation Linked with Postoperative Complications
the Cancer Therapy Advisor take:
According to a new study published in the Journal of the American College of Surgeons, researchers have found that having liver metastases and receiving chemotherapy are associated with higher splenic volume in patients with metastatic colorectal cancer, and the splenic volume increase is independently linked with major postoperative complications following hepatic resection.
For the study, researchers enrolled 80 patients with metastatic colorectal cancer and liver metastases who underwent hepatic resection. Of those, half received chemotherapy for 6 months before surgery while the other half did not receive preoperative chemotherapy. The patients who received preoperative chemotherapy were also compared to a group of 40 patients with benign disease who underwent cholecystectomy and a group of 40 patients with untreated non-metastatic colorectal cancer.
Results showed that the study group had significantly higher splenic volumes compared with the patients with benign disease (p < 0.001) and the patients with non-metastatic disease (p < 0.05) before chemotherapy. After 6 months of chemotherapy, the study group's splenic volumes were even higher, and the elevation was linked with any complication during surgery (p < 0.01) and major postoperative complications (p < 0.05).
Furthermore, patients with a 39% or higher increase in splenic volume were statistically significantly more likely to develop major complications after hepatic resection (p < 0.01). Of note, the researchers found no association between splenic volume increase and change in platelet count.
Splenic volume increase is independently linked with major postoperative complications following hepatic resection.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer